PPTA's North America division is actively engaged in setting an advocacy and priority agenda for patient access. Staff monitors pending legislation, informs government representatives and works diligently to advance positions that protect the interests of patients who rely on life-saving, plasma protein therapies (PPTs). The Federal Affairs advocates with Members of Congress and Congressional staff on legislative issues related to PPTs, access to therapies and reimbursement. The Association also works in state capitals throughout the U.S. to ensure patient access to therapies, reimbursement and implementation of the Affordable Care Act (ACA).
In North America, PPTA advocates on behalf of patients not only at the state and federal level in the United States but also in Canada:
The Hilfenhaus Award conferred to Prof. Farkas at the IPPC 2017 +
The 2017 Hilfenhaus Award was bestowed to Professor Henriette Farkas, MD, Ph.D., DSc, during IPPC 2017 for her work related to treating those suffering from Hereditary Angioedema (HAE) and working to improve treatments and patients’ quality of life. She is professor of allergology and clinical immunology at the Hungarian Angioedema Center at Semmelweis University in Budapest, Hungary.Read More
Highlights from IPPC 2017 +
Mr. Bruno Santoni, Executive Director, PPTA Europe, opened the well-attended IPPC 2017 welcoming the more than 300 attendees to Prague. PPTA thanks its sponsors who help make the IPPC possible. Download the IPPC app for a complete list of sessions and many of the presentations.Read More
PPTA Remembers John W. Walsh +